Back to Journals » International Journal of Nanomedicine » Volume 7

Fractionated photothermal antitumor therapy with multidye nanoparticles

Authors Gutwein LG, Singh AK, Hahn MA, Rule MC, Knapik JA, Moudgil BM, Brown SC, Grobmyer SR

Received 22 September 2011

Accepted for publication 24 November 2011

Published 20 January 2012 Volume 2012:7 Pages 351—357

DOI https://doi.org/10.2147/IJN.S26468

Review by Single-blind

Peer reviewer comments 4

Luke G Gutwein1, Amit K Singh2, Megan A Hahn2, Michael C Rule3, Jacquelyn A Knapik4, Brij M Moudgil2, Scott C Brown2, Stephen R Grobmyer1
1Division of Surgical Oncology, Department of Surgery, College of Medicine, 2Particle Engineering Research Center, 3Cell and Tissue Analysis Core, McKnight Brain Institute, 4Department of Pathology, University of Florida, Gainesville, FL, USA

Purpose: Photothermal therapy is an emerging cancer treatment paradigm which involves highly localized heating and killing of tumor cells, due to the presence of nanomaterials that can strongly absorb near-infrared (NIR) light. In addition to having deep penetration depths in tissue, NIR light is innocuous to normal cells. Little is known currently about the fate of nanomaterials post photothermal ablation and the implications thereof. The purpose of this investigation was to define the intratumoral fate of nanoparticles (NPs) after photothermal therapy in vivo and characterize the use of novel multidye theranostic NPs (MDT-NPs) for fractionated photothermal antitumor therapy.
Methods: The photothermal and fluorescent properties of MDT-NPs were first characterized. To investigate the fate of nanomaterials following photothermal ablation in vivo, novel MDT-NPs and a murine mammary tumor model were used. Intratumoral injection of MDT-NPs and real-time fluorescence imaging before and after fractionated photothermal therapy was performed to study the intratumoral fate of MDT-NPs. Gross tumor and histological changes were made comparing MDT-NP treated and control tumor-bearing mice.
Results: The dual dye-loaded mesoporous NPs (ie, MDT-NPs; circa 100 nm) retained both their NIR absorbing and NIR fluorescent capabilities after photoactivation. In vivo MDT-NPs remained localized in the intratumoral position after photothermal ablation. With fractionated photothermal therapy, there was significant treatment effect observed macroscopically (P = 0.026) in experimental tumor-bearing mice compared to control treated tumor-bearing mice.
Conclusion: Fractionated photothermal therapy for cancer represents a new therapeutic paradigm enabled by the application of novel functional nanomaterials. MDT-NPs may advance clinical treatment of cancer by enabling fractionated real-time image guided photothermal therapy.

Keywords: fluorescence, mesoporous silica, biodistribution, photothermal ablation, live animal imaging, near-infrared nanoparticle, breast cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Multi-dye theranostic nanoparticle platform for bioimaging and cancer therapy

Singh AK, Hahn MA, Gutwein LG, Rule MC, Knapik JA, Moudgil BM, Grobmyer SR, Brown SC

International Journal of Nanomedicine 2012, 7:2739-2750

Published Date: 1 June 2012

Readers of this article also read:

Synthesis, characterization, and antimicrobial activity of an ampicillin-conjugated magnetic nanoantibiotic for medical applications

Hussein-Al-Ali SH, El Zowalaty ME, Hussein MZ, Geilich BM, Webster TJ

International Journal of Nanomedicine 2014, 9:3801-3814

Published Date: 8 August 2014

Genetically engineered nanocarriers for drug delivery

Shi P, Gustafson JA, MacKay JA

International Journal of Nanomedicine 2014, 9:1617-1626

Published Date: 26 March 2014

Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection

Yang Z, Chen M, Yang M, Chen J, Fang W, Xu P

International Journal of Nanomedicine 2014, 9:327-336

Published Date: 6 January 2014

Erratum

Sørensen HT, Friborg S, Rungby J, Christiansen JS, Vaag A, Beck-Nielsen H

Clinical Epidemiology 2012, 4:49-50

Published Date: 20 December 2012

Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives

Federico C, Morittu VM, Britti D, Trapasso E, Cosco D

International Journal of Nanomedicine 2012, 7:5423-5436

Published Date: 1 November 2012

Biodistribution and pharmacokinetics of a telodendrimer micellar paclitaxel nanoformulation in a mouse xenograft model of ovarian cancer

Xiao W, Luo J, Jain T, Riggs JW, Tseng HP, Henderson PT, Cherry SR, Rowland D, and Lam KS

International Journal of Nanomedicine 2012, 7:1587-1597

Published Date: 27 March 2012

Anticancer efficacy of perillyl alcohol-bearing PLGA microparticles

Farazuddin M, Sharma B, Khan AA, Joshi B, Owais M

International Journal of Nanomedicine 2012, 7:35-47

Published Date: 5 January 2012